JoelZeffrenMD

Internal Medicine • Overland, MO

Physician

Join to view full profile

Are you Dr. Zeffren?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 8 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
2428 Woodson Rd
Overland, MO 63114
Phone+1 314-427-2424
Is this information wrong?

Summary

Dr. Joel Zeffren, MD is a board certified internist in Overland, Missouri.

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1957 - 1960
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1955 - 1957
St Louis Connect CareInternship, Internal Medicine, 1952 - 1953
Saint Louis University School of MedicineClass of 1952

Certifications & Licensure

American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

Reversible defect in renal concentrating mechanism in patients with hypercalcemia.
ZEFFREN, J. L., HEINEMANN, H. O.> ;Am J Med. 1962 Jul
41 citations
Reticulum Cell Sarcoma Terminating in Acute Leukemia
J. LEsilin Zeffren, John E. Ultmann> ;Blood. 1960 Feb 1
Effects of prolonged tolbutamide therapy on hepatic function and serum cholesterol of adult diabetic patients.
ZEFFREN, J. L., SHERRY, S.> ;Metab Clin Exp. 1957 Nov
4 citations
THE USE OF TOLBUTAMIDE IN THE MANAGEMENT OF ADULT DIABETES
Sol Sherry, J. Lester Zeffren, Abe E. Braverman, Norman W. Drey> ;Annals of the New York Academy of Sciences. 1975 Jul 1
Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
Lipton, A., Harvey, H., Givant, E., Hopper, K., Lawler, J., Matthews, Y., Hirsh, M., Zeffren, J.> ;J Immunother Emphasis Tumor Immunol. 1993 Feb
A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.
Whitehead, R. P., Figlin, R., Citron, M. L., Pfile, J., Moldawer, N., Patel, D., Jones, G., Levitt, D., Zeffren, J.> ;J Immunother Emphasis Tumor Immunol. 1993 Feb
Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate.
Zeffren, J., Yagoda, A., Kelsen, D., Winn, R.> ;Anticancer Res. 1984 Nov 01
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon.
Foon, K. A., Sherwin, S. A., Abrams, P. G., Longo, D. L., Fer, M. F., Stevenson, H. C., Ochs, J. J., Bottino, G. C., Schoenberger, C. S., Zeffren, J.> ;N Engl J Med. 1984 Nov 1
Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.
Bunn, P. A., Foon, K. A., Ihde, D. C., Longo, D. L., Eddy, J., Winkler, C. F., Veach, S. R., Zeffren, J., Sherwin, S., Oldham, R.> ;Ann Intern Med. 1984 Oct
Phase II trial of methyl-GAG in advanced renal cancer.
Zeffren, J., Yagoda, A., Watson, R. C., Natale, R. B., Blumenreich, M. S., Chapman, R., Howard, J.> ;Cancer Treat Rep. 1981 May 01
Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.
Olsen, E. A., Rosen, S. T., Vollmer, R. T., Variakojis, D., Roenigk, H. H., Diab, N., Zeffren, J.> ;J Am Acad Dermatol. 1989 Mar
Biologic therapy of cancer.
Dunton, A. W., Hanagan, J., Levitt, D., Spiegel, R. J., Zeffren, J.> ;N J Med. 1990 Nov
Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
Hirsh, M., Lipton, A., Harvey, H., Givant, E., Hopper, K., Jones, G., Zeffren, J., Levitt, D.> ;J Clin Oncol. 1990 Oct
A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors.
Huberman, M., Bering, H., Fallon, B., Tessitore, J., Sonnenborn, H., Paul, S., Zeffren, J., Levitt, D., Groopman, J.> ;Cancer. 1991 Oct 15
A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma.
Mittelman, A., Puccio, C., Ahmed, T., Zeffren, J., Choudhury, A., Arlin, Z.> ;Cancer. 1991 Oct 15
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin, R. A., Belldegrun, A., Moldawer, N., Zeffren, J., deKernion, J.> ;J Clin Oncol. 1992 Mar
Join now to see all